CNBC's Silvia Amaro looks at how investors around the world are digesting news of President Donald Trump's 100% tariff on branded drugs, and whether Europe's pharma giants will avoid the worst impact.
Breakdown
- The US will impose a 100 percent tariff on branded drug imports, with exemptions for companies building US plants. 13s
- European pharma firms are expected to be insulated from these tariffs due to the US-EU trade deal. 45s
- Major European companies like AstraZeneca, Roche, and Novartis have announced significant investments in US manufacturing. 1m 3s
- JP Morgan analysts say most large-cap European biopharma companies will largely avoid the new tariffs. 1m 27s
- Industry executives report sufficient US manufacturing capacity and positive trade balances, minimizing tariff impact. 1m 54s